CAS 218600-44-3
:acide 2-cyano-3,12-dioxooléana-1,9(11)-diène-28-oïque
- 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid
2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid
CAS :Formule :C31H41NO4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :491.6615(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-Cyano-2,2,6A,6B,9,9,12A-Heptamethyl-10,14-Dioxo-1,3,4,5,6,6A,6B,7,8,8A,9,10,12A,14,14A,14B-Hexadecahydropicene-4A(2H)-Carboxylic Acid
CAS :(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-Cyano-2,2,6A,6B,9,9,12A-Heptamethyl-10,14-Dioxo-1,3,4,5,6,6A,6B,7,8,8A,9,10,12A,14,14A,14B-Hexadecahydropicene-4A(2H)-Carboxylic AcidDegré de pureté :98%Masse moléculaire :491.66g/molBardoxolone
CAS :Bardoxolone (CDDO) inhibits iNOS, COX-2 in cells; IC50=0.4nM. Reduces ROS/RNS, DNA damage, & cancer growth; triggers apoptosis & boosts antioxidant genes.Formule :C31H41NO4Degré de pureté :97.9% - 98.97%Couleur et forme :SolidMasse moléculaire :491.66Bardoxolone
CAS :Produit contrôléApplications Bardoxolone is a synthetic oleanane triterpenoid that exerts multifunctional activities in the control of cellular growth and differentiation. Bardoxolone is capable of activating the transcription factor peroxisome proliferator activator receptor-γ (PPARγ), its apoptotic effects in malignant cells have been shown to occur independently of PPARγ. Bardoxolone was developed as an potential drug for the improvement of hyperglycemia, proteinuria, glomerulus structure, serum creatine, which may in turn be beneficial to treat diabetic kidney diseases, cancer and thromboembolic events.
References Shepler, B., et al.: Clinical. Therap., 34, 1237 (2012); Speranza, G., et al.: Cancer. Chemo. Pharmacol., 69, 431 (2012); Sporn, M.B., et al.: J. Natural. Prod., 74, 537 (2011);Formule :C31H41NO4Couleur et forme :NeatMasse moléculaire :491.66Bardoxolone
CAS :Bardoxolone methyl is a novel compound that has been shown to be a potent inducer of erythropoietin. It is also an inhibitor of the transcriptional factor, nuclear factor-κB (NF-κB), and it has been shown to have potent anti-inflammatory effects in vitro. In vivo studies have demonstrated that bardoxolone methyl significantly reduces the incidence and severity of bowel disease in a rat model. The drug also inhibits cardiac fibrosis and heart failure in rats with chronic kidney disease. Finally, bardoxolone methyl has been shown to increase natriuretic peptide levels in both mice and humans.Formule :C31H41NO4Degré de pureté :Min. 95%Couleur et forme :PowderMasse moléculaire :491.66 g/mol




